Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mareen Lüthen

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Cell Reports|April 16, 2020
Disentangling Pro-mitotic Signaling during Cell Cycle Progression using Time-Resolved Single-Cell ImagingManuela Benary, Stefan Bohn, Mareen Lüthen, et al.
Science Signaling|July 22, 2025
Reporter-based screening identifies RAS-RAF mutations as drivers of resistance to active-state RAS inhibitors in colorectal cancerOleksandra Aust, Moritz R T Thiel, Eric Blanc, et al.
Nature Communications|July 4, 2019
Cell type-dependent differential activation of ERK by oncogenic KRAS in colon cancer and intestinal epitheliumRaphael Brandt, Thomas Sell, Mareen Lüthen, et al.
Cell Reports|September 23, 2020
SFPQ Depletion Is Synthetically Lethal with BRAF<sup>V600E</sup> in Colorectal Cancer CellsKathleen Klotz-Noack, Bertram Klinger, Maria Rivera, et al.
EMBO Molecular Medicine|August 19, 2021
Mitogen-activated protein kinase activity drives cell trajectories in colorectal cancerFlorian Uhlitz, Philip Bischoff, Stefan Peidli, et al.
Cancer Research|November 8, 2022
Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic CancerCraig M Goodwin, Andrew M Waters, Jennifer E Klomp, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Cell Reports|April 16, 2020
Disentangling Pro-mitotic Signaling during Cell Cycle Progression using Time-Resolved Single-Cell ImagingManuela Benary, Stefan Bohn, Mareen Lüthen, et al.
Science Signaling|July 22, 2025
Reporter-based screening identifies RAS-RAF mutations as drivers of resistance to active-state RAS inhibitors in colorectal cancerOleksandra Aust, Moritz R T Thiel, Eric Blanc, et al.
Nature Communications|July 4, 2019
Cell type-dependent differential activation of ERK by oncogenic KRAS in colon cancer and intestinal epitheliumRaphael Brandt, Thomas Sell, Mareen Lüthen, et al.
Cell Reports|September 23, 2020
SFPQ Depletion Is Synthetically Lethal with BRAF<sup>V600E</sup> in Colorectal Cancer CellsKathleen Klotz-Noack, Bertram Klinger, Maria Rivera, et al.
EMBO Molecular Medicine|August 19, 2021
Mitogen-activated protein kinase activity drives cell trajectories in colorectal cancerFlorian Uhlitz, Philip Bischoff, Stefan Peidli, et al.
Cancer Research|November 8, 2022
Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic CancerCraig M Goodwin, Andrew M Waters, Jennifer E Klomp, et al.
Pageof 1